The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
Open accessAbstract
Background Safety and efficacy have been shown in a phase 1 dose-escalation study involving a unilateral subretinal injection of a recombinant adeno-associated virus (AAV) vector containing the RPE65 gene (AAV2-hRPE65v2) in individuals with inherited retinal dystrophy caused by RPE65 mutations. This finding, along with the bilateral nature of the disease and intended use in treatment, prompted us to determine the safety of administration of AAV2-hRPE65v2 to the contralateral eye in patients enrolled in the phase 1 study.Methods In this follow-on phase 1 trial, one dose of AAV2-hRPE65v2 (1.5 × 10(11) vector genomes) in a total volume of 300 μL was subretinally injected into the contralateral, previously uninjected, eyes of 11 children and adults (aged 11-46 years at second administration) with inherited retinal dystrophy caused by RPE65 mutations, 1.71-4.58 years after the initial subretinal injection. We assessed safety, immune response, retinal and visual function, functional vision, and activation of the visual cortex from baseline until 3 year follow-up, with observations ongoing. This study is registered with ClinicalTrials.gov, number NCT01208389.Findings No adverse events related to the AAV were reported, and those related to the procedure were mostly mild (dellen formation in three patients and cataracts in two). One patient developed bacterial endophthalmitis and was excluded from analyses. We noted improvements in efficacy outcomes in most patients without significant immunogenicity. Compared with baseline, pooled analysis of ten participants showed improvements in mean mobility and full-field light sensitivity in the injected eye by day 30 that persisted to year 3 (mobility p=0.0003, white light full-field sensitivity p<0.0001), but no significant change was seen in the previously injected eyes over the same time period (mobility p=0.7398, white light full-field sensitivity p=0.6709). Changes in visual acuity from baseline to year 3 were not significant in pooled analysis in the second eyes or the previously injected eyes (p>0.49 for all time-points compared with baseline).Interpretation To our knowledge, AAV2-hRPE65v2 is the first successful gene therapy administered to the contralateral eye. The results highlight the use of several outcome measures and help to delineate the variables that contribute to maximal benefit from gene augmentation therapy in this disease.Funding Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia, Spark Therapeutics, US National Institutes of Health, Foundation Fighting Blindness, Institute for Translational Medicine and Therapeutics, Research to Prevent Blindness, Center for Advanced Retinal and Ocular Therapeutics, Mackall Foundation Trust, F M Kirby Foundation, and The Research Foundation-Flanders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the presence of pre-existing neutralizing antibodies to AAV does not appear to correlate with a higher risk of retinal inflammation or reduced therapeutic efficacy, provided that the AAV vector is delivered via the subretinal route.27, 28, 29”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from one participant who unfortunately devel oped culture-positive bacterial endophthalmitis after surgery, no par ticipants demonstrated intraocular inflammation or CRA within three years of second eye treatment.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bennett et al., 2016
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, in the clinical setting, ocular and intrathecal AAV gene delivery have shown limited transgene-related immune responses, possibly due to their compartmentation and reduced antigen presentation [16, 132, 133].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [133]
In the citing paper
“Phase I to III clinical trials for Luxturna have consistently demonstrated its ability to bring about sustained improvements in low luminance vision in otherwise blind patients [Maguire 2009; Bennett 2016; Russell 2017].”
From Correcting visual loss by genetics and prosthetics (2020) · cites this paper as Bennett 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Self-citationLong-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
Holladay, J. T. (2004) · Journal of Cataract & Refractive Surgery · doi:10.1016/j.jcrs.2004.01.014 · Cited by 688
Cideciyan, A. V., Alemán, T. S., Boye, S. L., Schwartz, S., Kaushal, S., Román, A. J., Pang, J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 674
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Research works printed but not linked: 1
- Amado, 2010, Safety and efficacy of subretinal re-administration of an AAV2 vector in large animal models: implications for studies in humans, Sci Transl Med, 2, 21ra16
Cited by
Sorted by citations
Items 401–463 of 463
Reflections on the Last 25 Years of the American Otological Society and Thoughts on its Future
Welling, D. B., & Jackler, R. K. (2018) · Otology & Neurotology · doi:10.1097/mao.0000000000001760 · Cited by 1
Neuromodulation Using Optogenetics and Related Technologies
Pedersen, N. P., & Gross, R. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805353-9.00035-8 · Cited by 2
Hassall, M., & Simunovic, M. P. (2020) · Springer eBooks · doi:10.1007/978-981-15-7644-7_35 · Cited by 1
Gene Therapy, Diet and Drug Approaches to Treating Inherited Retinal Disease
Simunovic, M. P., Mack, H. G., Ayton, L. N., & Hassall, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00154-7 · Cited by 1
Gene Therapy for Inherited Metabolic Diseases
Longo, N., & Lai, K. (2022) · Springer eBooks · doi:10.1007/978-3-030-94510-7_8 · Cited by 1
Dynamic structural remodeling of the human visual system prompted by bilateral retinal gene therapy
Ashtari, M., Cook, P. A., Lipin, M. Y., Yu, Y., Ying, G., Maguire, A. M., Bennett, J., Gee, J. C., & Zhang, H. G. (2023) · Current Research in Neurobiology · doi:10.1016/j.crneur.2023.100089 · Cited by 1
Self-citationOcular Gene Therapy: Literature Review
Naser, M., Nasr, M., & Shehata, L. H. (2023) · International Journal of Progressive Sciences and Technologies · doi:10.52155/ijpsat.v40.2.5623 · Cited by 1
Jalligampala, A., Young, J. M., Feist, J., Wang, W., Barone, F., Alston, D. C., Fransen, J. W., Jaikumar, G., Kamboj, K., Mooreman, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.25.678625 · Cited by 1
Utilities of AAV vectors in in vivo phenotypic screening and functional studies
Lee, K. J., & Li, Y. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1292442
New Perspectives in Genetic Therapies
Fischer, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-69974-5_7
Gene and Cell Therapy: Tearing Down Walls
VandenDriessche, T. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.29074.tva
Molecular insights into PCARE-associated retinal disease
Serrano, J. C. C. (2018) · Radboud Repository (Radboud University)
An Update on Ocular Gene Therapy for Monogenic and Multifactorial Retinal Diseases
Hou, A. Y., & Kiss, S. (2019) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126419876750
Rewriting the Future: Promises and Limits of Germline Gene Editing in Craniofacial Surgery
Davitt, M. F., Mascharak, S., desJardins-Park, H. E., Chinta, M. S., Wan, D. C., & Longaker, M. T. (2020) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000006602
[Expression pattern of different serotypes of adeno-associated viral vectors in mouse retina].
Hu, S., & Yang, L. (2020) · PubMed Central · doi:10.19723/j.issn.1671-167x.2020.05.008
Retinal Surgical Techniques for Gene Therapy
Muthiah, M. N., Wong, S. C., Michaelides, M., & Bainbridge, J. W. (2021) · Springer eBooks · doi:10.1007/978-981-33-4168-5_35
Präventionsfalle und Selbstschreck
Walach, H. (2021) · Kompass Ophthalmologie · doi:10.1159/000516871
Stingl, K. T., Kempf, M., Bartz‐Schmidt, K. U., Dimopoulos, S., Reichel, F., Jung, R., Kelbsch, C., Kohl, S., Kortüm, F. C., Nasser, F., et al. (2021) · Kompass Ophthalmologie · doi:10.1159/000519131
Voretigene Neparvovec challenges in clinical practice
Daruich, A., Cotteret, C., Cisternino, S., Robert, M. P. A., & Brémond‐Gignac, D. (2021) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2021.09.003
Moodle:データベース構築の実際(2)「小テスト」と「オンラインテキスト」について
表, 正. (2010)
Genetic disorders causing non-syndromic retinopathy
(2022) · Elsevier eBooks · doi:10.1016/b978-0-12-813944-8.00013-5
RNA Base Editing Technologies for Gene Therapy
Deswal, S. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch15
Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia
Кадышев, В. В., Zolnikova, I. V., Khalanskaya, O. V., Stepanova, A. A., & Kutsev, S. I. (2022) · Russian Annals of Ophthalmology · doi:10.17116/oftalma202213804149
New Avenues of Delivery (Subretinal Gene Therapy, Port Delivery, Suprachoroidal)
Nair, A. A., Chaili, S., & Law, J. C. (2023) · Current practices in ophthalmology · doi:10.1007/978-981-99-1661-0_19
High, K. A. (2023) · PubMed Central
Self-citationRecent Development in in vivo Clinical Gene Therapy Platforms
Murphy, J. E., & Owens, J. M. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch2
Publication trends of Leber congenital amaurosis researches: a bibliometric study during 2002-2022
Huang, X.-X., Xie, M., Sun, Y.-Q., Zhao, X., Chen, Y., Chen, J., Han, S.-Y., Zhou, M., & Sun, X. (2024) · International Journal of Ophthalmology · doi:10.18240/ijo.2024.08.17
Estimating Australian Population Utilities for Inherited Retinal Disease Using Time Trade-Off
Farris, M., Goodall, S., Lourenço, R. D. A., Mulhern, B. J., Manipis, K., Meshcheriakova, E., & Lewandowska, M. (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00515-5
Mullagulova, A. I., Shaimardanova, A. A., Mukhamedshina, Y. O., Solovyeva, V. V., Ibrahim, A., & Rizvanov, A. A. (2024) · Učënye zapiski Kazanskogo universiteta. Seriâ Estestvennye nauki/Učënye zapiski Kazanskogo universiteta. Seriâ Estestvennye nauki/Učenye zapiski Kazanskogo gosudarstvennogo universiteta. Seriâ Estestvennye nauki · doi:10.26907/2542-064x.2024.4.683-703
Kim, S. R., Kim, J. H., Yoon, W. T., & Lew, Y. J. (2025) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2025.66.1.36
Imaging methods for monitoring optic nerve regeneration
Yu, K. C., Kasi, A., James, R. A., Xue, Y., & Chan, K. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15580-2.00002-3
Singh, M. S., Guo, S., Toomey, C. B., McNally, M. M., Harris‐Bookman, S., Li, K. V., Agakishiev, D., Wei, S., Lee, S., Perrino, K. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.25.640217
Genetic Pathways in Inherited Retinal Disorders and Targets for Therapy
Zhou, A. Z., Şahlı, E., Jenny, L. A., Ling, J., & Tsang, S. H. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197659403.003.0026
Retinal Epithelial Neutralization Assay Optimizes AAV Serotype Selection for Ocular Gene Therapy
Li, Y., Chen, Y., Huo, N., Jia, Z., Huang, H., Zhao, Z., Wu, S., & Hou, L. (2025) · Viruses · doi:10.3390/v17070988
RPE65-associated Retinal Diseases and Ocular Genetic Studies
Erol, M. A., & Kaplan, F. B. (2025) · Güncel Retina Dergisi (Current Retina Journal) · doi:10.37783/crj-0522
Deng, W., Brothers, B. A., Sechrest, E. R., Ma, L., Ashcraft, M. E., Guan, T., Barbera, R., Cahill, M., Shaw, L., Chen, B., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09045-0
Menzie, J., Modi, J., Xu, H., Bent, A., Trujillo, P., Medley, K., Jimenez, E., Shen, J., Marshall, M., Tao, R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13172963
Liu, X., Pacwa, A., Bresciani, G., Świerczyńska, M., Dorecka, M., & Smedowski, A. (2024) · Figshare · doi:10.6084/m9.figshare.26754157
Menzie, J., Modi, J., Xu, H., Bent, A., Trujillo, P., Medley, K., Jimenez, E., Shen, J., Marshall, M., Tao, R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13172966
Menzie, J., Modi, J., Xu, H., Bent, A., Trujillo, P., Medley, K., Jimenez, E., Shen, J., Marshall, M., Tao, R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13172960
Concise Review of Advances in Gene Therapy for Vascular Disorders
Peduk, A. (2025) · Gene Editing · doi:10.29228/genediting.76698
Exploration and Application of Multiluminance Mobility Test in Bietti Crystalline Dystrophy
Chen, Y., Wu, N., Meng, X., Long, Y., Ren, J., Wang, Y., Liu, X., & Liu, Y. (2026) · Translational Vision Science & Technology · doi:10.1167/tvst.15.2.29
Vasquez, J. M., Mackey, H. L., Rostami, M. R., Leopold, P. L., & Crystal, R. G. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201709
Alvisi, M., Roberts, L., Roessig, L., Balderson, D. E., Sanganalmath, S. K., Braun, M., Gordon, S. N., Lacey, S. F., Pandya, P., & Hajjar, R. J. (2026) · Human Gene Therapy · doi:10.1177/10430342261430244
Role of the Glycogen Synthase Kinase 3 for the Retinal Development and Homeostasis
Braginskaja, E. (2018) · theses.fr (ABES) · doi:10.70675/72532a81z164ez4786z8c84zaf55afbdfa1d
Implication de FGF9 et de FGF19 dans la fibrose pulmonaire idiopathique
Justet, A. (2020) · theses.fr (ABES) · doi:10.70675/6e72f095z0cb6z4dd3zb204z88d1b08b9910
Development of safe and efficient aav vectors for retinal gene therapy
Khabou, H. (2018) · theses.fr (ABES) · doi:10.70675/aa896663z9772z4d87z9bd1z247af1f0e3f1
Label-Free Quantification of Virus Titer Using Machine Learning-Enhanced Immunosensors
Shukla, R. P., Sun, H., Wang, J., Twiddy, J. S., Shastry, S., Hosseini, M., Menegatti, S., & Daniele, M. A.-A. (2026) · IEEE Sensors Journal · doi:10.1109/jsen.2026.3681515
Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-7688-3_3
Owliaee, I., Teimoori, A., Shoushtari, M., & Shojaeian, A. (2026) · Clinical ophthalmology · doi:10.2147/opth.s593854
Widespread AAV-mediated CSPG digestion impairs functional recovery after cervical spinal cord injuryPreprint
Metcalfe, M., Steward, O., & Gallardo, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.22.727165
Kwon, J., Kim, Y. J., Kim, S.-H., Kwon, O.-S., Jang, H., Choi, Y., Na, H.-J., Han, N., Chun, Y., Han, J. H., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102971
Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular ToxicityPreprint
Gardner, A., Hong, C. M., Zhao, S. R., Daniels, A., & Cepko, C. L. (2026) · eLife · doi:10.7554/elife.111783
Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular ToxicityPreprint
Gardner, A., Hong, C. M., Zhao, S. R., Daniels, A., & Cepko, C. L. (2026) · eLife · doi:10.7554/elife.111783.1
Amato, A., Iarossi, G., & Stephenson, K. A. J. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.07.039
Hauser, B. M., Place, E., Luo, Y., Comander, J., Nathan, A., Pierce, E. A., Bujakowska, K. M., Gaiha, G. D., & Rossin, E. J. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.10.60
Self-citationVoretigene Neparvovec (Luxturna) for Biallelic RPE65–Associated Retinal Dystrophy: Systematic Review
Butt, A. B., Zaman, M., Mihalache, A., KamaliZonouzi, S., Zadeh, P. B., Shah, Y. R., Popovic, M. M., Kertes, P. J., Ballios, B. G., Vincent, A., et al. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.08.043
From retina to brain: Viral tools for targeting retinal cells and mapping visual circuits
Talla, V., & Park, K. K. (2026) · Molecules and Cells · doi:10.1016/j.mocell.2026.100403
Durable Safety and Efficacy of Voretigene Neparvovec-Rzyl in Postapproval Studies in the USA
Bennett, J. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.08.029
Self-citationRethinking nonsense suppression therapies in inherited retinal diseases
Ren, C., Hu, C., Hu, M., Yang, Y., & Lu, F. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.09.017
Metadata
- Authors
- Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., Cross, D. R., Aravand, P., Cyckowski, L. L., Bennicelli, J. L., Mingozzi, F., Auricchio, A., Pierce, E. A., Ruggiero, J., Leroy, B. P., Simonelli, F., High, K. A., & Maguire, A. M.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Spark Therapeutics (United States) (US)
- University of Pennsylvania (US)
- Federico II University Hospital (IT)
- Massachusetts Eye and Ear Infirmary (US)
- University of Campania "Luigi Vanvitelli" (IT)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 388
- Issue
- 10045
- Pages
- 661-672
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC5351775
- OpenAlex
- W2473832992
- Cited by
- 461
- References
- 29
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 31 · 2023: 41 · 2022: 50 · 2021: 54 · 2020: 66 · 2019: 38 · 2018: 55 · 2017: 56 · 2016: 8
- FWCI
- 27.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- FWO Flanders (grant OZP 3G004306)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- RPE65 mutations, inherited retinal disease, subretinal gene therapy, recombinant adeno-associated virus vectors, immune response, visual function, mobility, visual cortex activation, pediatric patients
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adolescent, Adult, Blindness, Child, Female, Follow-Up Studies, Genetic Vectors, Humans, Male, Middle Aged, Mutation, Occipital Lobe, Vision, Ocular, Genetic Therapy, Linear Models, Age of Onset, Retinal Rod Photoreceptor Cells, Retinal Cone Photoreceptor Cells, Retreatment, Evidence-Based Medicine, cis-trans-Isomerases, Injections, Intraocular, Administration, Ophthalmic, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
